Pfizer lifts 2022 forecast for Covid-19 vaccine sales as profits rise / Photo: SPENCER PLATT - GETTY IMAGES NORTH AMERICA/AFP/File
-
ECB holds rates steady after Lagarde says to quit early
-
US economy posts strong growth, inflation stubbornly high in challenge to Trump
-
ECB chief Lagarde to step down early, triggering succession race
-
French businessman takes over 2030 Winter Olympics amid leadership turmoil
-
VW says 'no time to lose' to slash costs after 5.8 billion euro loss
-
Stock markets diverge on corporate earnings, tech jitters
-
Oil majors reap bumper profits as Mideast war drives prices
-
TotalEnergies profit hits record on high oil prices
-
Taiwan says Pakistan briefly closed airspace to Taiwanese flights
-
Afghanistan opium poppy cultivation surges despite Taliban govt ban: UN
-
Samsung logs record quarterly profits despite investor AI jitters
-
Microsoft beats expectations fueled by Azure cloud business
-
Shares in Google owner Alphabet plummet on profit miss, ad slowdown
-
Shares in Google owner Alphabet sink on profit miss, ad slowdown
-
US Fed holds interest rates steady despite 'too high' inflation
-
Pioneering US labor leader Dolores Huerta dies at 96
-
Airbus aims for record deliveries despite disappointing quarter
-
US Fed holds interest rates steady despite surging inflation
-
Real Madrid, La Liga apology over Mbappe shows power of Chinese market
-
US labor leader Dolores Huerta dead: family
-
'Cruise for life' strands passengers in Cambodia as operator goes bust
-
French firm Safran helps build aircraft wings of the future in UK factory
-
Canada hikes rates to contain oil price surge caused by Iran war
-
World Bank warns of worsening food insecurity as commodity prices soar
Pfizer lifts 2022 forecast for Covid-19 vaccine sales as profits rise
Pfizer reported higher quarterly profits Tuesday as it lifted its full-year forecast for coronavirus vaccine sales and predicted Covid-19 would yield billions more in revenues for the forseeable future.
The big US drugmaker now expects 2022 sales of the Comirnaty Covid-19 vaccine of $34 billion, up $2 billion from the prior outlook.
Pfizer maintained its projection of $22 billion in annual sales for its Paxlovid therapeutic for Covid-19.
More than two years into the pandemic, Chief Executive Albert Bourla predicted revenues for Covid-19 products would persist even though they are likely to fall from their 2022 levels.
"We believe our Covid-19 franchises will remain multi-billion revenue generators for the forseeable future, which should serve as a buffer for any unforeseen challenges with other products in our portfolio," Bourla said in prepared remarks.
The most recent quarter included an 83 percent surge in Covid-19 vaccine revenues in the United States, driven by deliveries of the latest booster shot for the Omicron BA.4/BA.5-adapted bivalent vaccine.
Overall, Pfizer reported profits of $8.6 billion in the third quarter, up six percent from the year-ago period on a six percent drop in revenues to $22.6 billion.
Bourla said Pfizer was on track to launch up to 19 new products in the next year and a half. He highlighted potential "blockbuster" products for respiratory syncytial virus (RSV), Ulcerative colitis and Migraine.
Bourla said the product pipeline should alleviate "understandable" questions about Pfizer's growth potential in the 2025 to 2030 given the loss of some $17 billion in revenues due to patent expirations.
Shares of Pfizer rose 3.5 percent to $48.20 in pre-market trading.
X.Cheung--CPN
